Safety risks were cited previously When the FDA added a number of injectable peptides to its list of restricted substances in 2023, it cited safety risks including cancer and liver, kidney and heart problems
GHK-Cu is a copper-bound tripeptide reference compound commonly utilized in controlled laboratory and in-vitro research environments examining peptide-mediated cellular signaling, copper-dependent biochemical pathways, and tissue-related research models
The authors research whether TB-500 may tone down this signaling and suggest that the peptide may increase the level of miR-146a, a small regulatory RNA molecule whose role may be to act as an internal brake on inflammatory signaling pathways
found that a topical GHK-Cu treatment enhanced the healing of ulcers in patients with diabetes and reduced the incidence of ulcer infection [7]
The other was cited for marketing supplements with unapproved drug claims, while also failing to comply with dietary supplement CGMP requirements
Are there hidden costs beyond the initial price of stem cell therapy